AveXis, Inc.
http://avexis.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From AveXis, Inc.
Zolgensma First To Be Subject To New German Data Collection Rules
The G-BA has explained in more detail the procedures for mandating post-launch evidence generation under new legislation introduced in 2019.
Novartis Shows Importance Of Gene Therapy With AveXis Name Change
Novartis has completed its absorption of AveXis and rebranded the acquired gene therapy specialist that developed the soon-to-be SMA blockbuster Zolgensma despite struggling to meet the data integrity standards of regulators and big pharma.
Roctavian’s Durability: For The Price, Payers Wanted Longer-Term Proof Anyway
FDA’s decision to seek two more years of data for BioMarin’s gene therapy for hemophilia A ‘makes perfect sense,’ Harvard Pilgrim Health Care’s Michael Sherman says.
Zolgensma First To Be Subject To New German Data Collection Rules
The G-BA has explained in more detail the procedures for mandating post-launch evidence generation under new legislation introduced in 2019.
Company Information
- Other Names / Subsidiaries
-
- BioLife Cell Bank, Inc.